| Abstract [eng] |
Cancer develops more and more people in Lithuania and the world. Therefore important to find out factors that may improve early diagnosis, treatment. The aim of research: To investigate, does the special natural IgM class antibodies to endotoxins leads longer people suffering from larynx and pharynx cancer survival The task of (the) research: 1. to establish, does IgMNAE content in blood affect survival of patients with larynx and pharynx cancer. 2. To assess the spread of cancer stage (FIGO) and IgMNAE content in blood influence to survival. 3. To investigate the of the disease stage (TNM) and IgMNAE content in blood influence to survival. 4.Cellular immunity and IgMNAE in blood influence to survival. 5. Investigate external cancer risk factors (smoking and alcohol) and IgMNAE content in blood influence to survival Methods: Was used tumor immunological laboratories 1988-1990 routine work “Cancer risk and oncological patients immunological researches” magazines, Vilnius University Oncology institute data of existing outpatients and cancer registry, following about: 78 trial men with larynx and pharynx cancer. Data analysis was performed using statistical package for data analysis SPSS version 17.0. To evaluate the difference between the groups used (chi-square) method), Kruscal-Wallis H test with values of p < 0,05 being defined as significant. Survival analysis was performed using the Kaplan-Meier method. Results: For patients with the blood of survival time median equal to 17 months, without – 11 months. Until the end of the observation survived 13.6 percent with IgMNAE and without IgMNAE – 13 percent. The spread of cancer stage (FIGO) and IgMNAE content in blood do not contribute to survival. Patients with IgMNAE in blood with one-year survival in II 66%, III 75%, IV 50 % stage and accordingly without IgMNAE 50%, 57%, 14%. There was no statistically significant difference obtains between T and IgMNAE content in blood and survival. N stage determinated the survival of cancer patients. Persons having established No stage gone through longer regardless of was found IgMNAE in blood or not p<0,05. Leukocytes in blood and IgMNAE had no effect to survival for patients with larynx and pharynx cancer. Increased (P> 0.05). Increased lymphocytes content in blood improves the survival rate p<0,05, regardless of IgMNAE content in patients’ blood. Conclusion: The specific IgMNAE content in blood serum does not have a positive effect for patients with larynx and pharynx cancer survival. Survival depends from the tumor spread to lymph nodes (N) and lymphocytes content in the blood. |
